Abstract:
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment or prevention of lipid disorders, metabolic disorders and cell-proliferative diseases. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in cholesterol metabolism. The subject compounds are particularly useful in the treatment of obesity, diabetes, hypercholesterolemia, atherosclerosis and hypolipoproteinemia.
Abstract:
Permanent magnets are mounted on a rotor of an electrical motor by an apparatus that keeps an adhesive bonding layer between the magnet and rotor in compression over wide variations in temperature and speed of rotation. The mechanical stresses on the magnets are controlled using compliant layers and spacers. The apparatus allows the removal and replacement of individual magnets.
Abstract:
A portable device for dispensing a fragrance comprising a housing (1) containing a fragrance element (3) and at least one aperture (5) in a side of the housing (1) in the vicinity of one end (6) of the housing to release fragrance from the housing (1). A lid is attached to the housing (1) to selectively open and close the aperture (5). The one end (6) of the device is shaped to abut the lower end of a users nose such that in use the fragrance can be inhaled through the aperture (5) to the nasal passage of the user.
Abstract:
An accident and emergency trolley supports and transports a patient, and includes a surface overlying an upper frame which is supported on a base frame in order to be raised and lowered relative to the base frame. The upper frame is mounted at its periphery on opposed radius arms connected to respective first and second actuators, which are operated by foot-operated pedals. The pedals are disposed on one or either side of the trolley such that operation of any single pedal enables the trolley to be raised at either end or both ends simultaneously. The opposed radius arms provide an uninterrupted window under the trolley allowing for X-ray/imaging.
Abstract:
Low weight and non-square carpet tile suitable for use in mass transit vehicles, particularly passenger aircraft. The carpet tile preferably weighs less than about 82 ounces per square yard. The carpet tile of this invention may have a carpet pile and at least one backing layer. The backing layer may use a low weight filler material. The carpet tiles satisfy transportation industry standards for flame, smoke and toxicity.
Abstract:
Low weight and non-square carpet tile suitable for use in mass transit vehicles, particularly passenger aircraft. The carpet tile preferably weighs less than about 82 ounces per square yard. The carpet tile of this invention may have a carpet pile and at least one backing layer. The backing layer may use a low weight filler material. The carpet tiles satisfy transportation industry standards for flame, smoke and toxicity.
Abstract:
A metal substrate is coated with a layer of ceramic, by spraying droplets of a slurry of a ceramic precursor onto the substrate, the substrate being at a temperature between 500° C. and 750° C. The ceramic comprises alumina, and is made macroporous by spraying a mixture of alumina sol and alumina particles with no more than 35% by weight of dispersible alumina. Spraying onto a red-hot surface in this fashion leads to a very marked improvement in adhesion of the resulting ceramic to the metal substrate. A catalytically active material may then be incorporated in the ceramic layer, so as to form a catalyst structure (16).
Abstract:
The invention provides an odour-absorbing clothes cover (2) comprising an odour-absorbing sheet material (4), the sheet material defining an enclosure, arranged, in use, to receive an item of clothing (22), the enclosure comprising an opening formed in the front surface of the enclosure. The invention also extends to a method of removing or mitigating odours from an item of clothing.
Abstract:
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR11, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH═CH; X is a hydrocarbyl group optionally substituted by one or more R12 groups; R10 and R11 are each independently II or alkyl; R1-R4 are each independently II or (CII2)mR12, where m is O, 1, 2, or 3; each R12 is independently (CH2)aR16, where each R16 is independently selected from O(CH2)bR13, R13, COR13, COOR13, CN, CONR13R14, NR13R14, NR13COR14, SR13, SOR13, SO2R13, NR13SO2R14, SO2OR13, SO2NR13R14, halogen, CF3, and NO2, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; R13 and R14 are each independently H or (CH2)nR15, where n is 0, 1, 2, or 3; and each R15 is independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO— alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.
Abstract translation:本发明涉及式(I)化合物或其药学上可接受的盐,其中Z为NR11,NHCO,NHSO2,NHCH2,CH2,CH2CH2或CH-CH; X是任选被一个或多个R 12基团取代的烃基; R 10和R 11各自独立地为II或烷基; R1-R4各自独立地为II或(CII2)mR12,其中m为0,1,2或3; 每个R 12独立地为(CH 2)a R 16,其中每个R 16独立地选自O(CH 2)b R 13,R 13,COR 13,COOR 13,CN,CONR 13 R 14,NR 13 R 14,NR 13 COR 14,SR 13,SOR 13,SO 2 R 13,NR 13 SO 2 R 14,SO 2 R 13,SO 2 NR 13 R 14, CF 3和NO 2,并且其中每个a是0,1,2或3,b是0,1,2或3; R 13和R 14各自独立地为H或(CH 2)n R 15,其中n为0,1,2或3; 并且每个R 15独立地选自烷基,环烷基,杂芳基,芳烷基,芳基和杂环烷基,其各自可以任选被一个或多个选自卤素,OH,CN,COO-烷基,芳烷基,SO 2 - 烷基,SO 2 - 芳基,COOH,CO-烷基,CO-芳基,NH 2,NH-烷基,N(烷基)2,CF 3,烷基和烷氧基,其中所述烷基和烷氧基可进一步被一个或多个OH基取代。 本发明的其它方面涉及包含式I化合物的药物组合物,以及式(I)化合物在制备用于治疗多种病症(包括增殖性病症,病毒性疾病,中风等)的药物中的用途。
Abstract:
Glycosidicaily stabilised macromolecules, such as proteins and peptides, have substantially greater stability in the presence of hydrofluoroalkane propellants for dispensing from metered dose inhalers, when formulated with polyhydroxylated polyalkenes such as PVA.